Ticker >

Ipca Laboratories share price

Ipca Laboratories Ltd.

NSE: IPCALAB BSE: 524494 SECTOR: Pharmaceuticals & Drugs  119k   670   87

1347.25
+23.30 (1.76%)
NSE: Today, 04:11 PM

Price Summary

Today's High

₹ 1356.3

Today's Low

₹ 1319.25

52 Week High

₹ 1374.6

52 Week Low

₹ 669.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

34180.3 Cr.

Enterprise Value

33896.85 Cr.

No. of Shares

25.37 Cr.

P/E

62.09

P/B

5.39

Face Value

₹ 1

Div. Yield

0.3 %

Book Value (TTM)

₹  249.98

CASH

1706.06 Cr.

DEBT

1422.61 Cr.

Promoter Holding

46.3 %

EPS (TTM)

₹  21.7

Sales Growth

6.83%

ROE

8.91 %

ROCE

11.77%

Profit Growth

-41.22 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 22 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.83%
3 Year10.01%
5 Year12.58%

Profit Growth

1 Year-41.22%
3 Year-8.14%
5 Year16.75%

ROE%

1 Year8.91%
3 Year17.61%
5 Year17.52%

ROCE %

1 Year11.77%
3 Year20.55%
5 Year19.85%

Debt/Equity

0.2421

Price to Cash Flow

44.84

Interest Cover Ratio

17.195295640915

CFO/PAT (5 Yr. Avg.)

1.03678258872617

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 46.3 0
Dec 2023 46.29 0
Sep 2023 46.29 0
Jun 2023 46.29 0
Mar 2023 46.29 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 20.5535146673733% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 17.195295640915.
  • The Company has been maintaining an effective average operating margins of 20.9084952140149% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 79.6778173904088 days.
  • Company has a healthy liquidity position with current ratio of 2.90571469441762.
  • The company has a good cash flow management; CFO/PAT stands at 1.03678258872617.

 Limitations

  • The company has shown a poor profit growth of -8.14283859176873% for the Past 3 years.
  • The company has shown a poor revenue growth of 10.0067634488213% for the Past 3 years.
  • The company is trading at a high PE of 62.09.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 1440.11 1401.63 1488.71 1662.67 1506.83
Total Expenditure 1229 1225.99 1191.18 1353.69 1233.34
Operating Profit 211.11 175.64 297.53 308.98 273.49
Other Income 24.2 33.47 43.16 36.14 16.89
Interest 10.43 17.69 30.76 38.64 27.21
Depreciation 58.38 59.21 60.35 61.35 63.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 166.5 132.21 249.58 245.13 200.15
Tax 51.32 47.39 83 83 63.21
Profit After Tax 115.18 84.82 166.58 162.13 136.94
Adjusted EPS (Rs) 4.54 3.34 6.57 6.39 5.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 3605.66 4337.82 5114.11 5405.42 5774.72
Total Expenditure 2926.87 3439.48 3663.9 4220.01 4886.6
Operating Profit 678.79 898.34 1450.21 1185.41 888.12
Other Income 71.57 84.16 128.6 108.76 137.34
Interest 21.09 18.84 11.13 10.41 46.34
Depreciation 171.88 178.69 187.72 209.65 228.63
Exceptional Items 0 0 0 0 0
Profit Before Tax 557.39 784.97 1379.96 1074.11 750.49
Tax 102.48 132.51 239.19 213.74 244.79
Net Profit 454.91 652.46 1140.77 860.37 505.7
Adjusted EPS (Rs.) 18 25.82 44.97 33.91 19.93

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 25.27 25.27 25.37 25.37 25.37
Total Reserves 3111.39 3652.27 4727.35 5450.39 5851.93
Borrowings 133.94 78.38 9.13 395.18 651.78
Other N/C liabilities 173.1 187.05 182.69 213.77 240.11
Current liabilities 1013.84 1241.6 1065.59 1353.73 1677.78
Total Liabilities 4457.54 5184.57 6010.13 7438.44 8446.97
Assets
Net Block 1740.1 1840.97 1868.6 2153.09 2478.66
Capital WIP 35.72 69.77 180.85 293.37 114.31
Intangible WIP 30.24 14.42 1.15 3.78 8.71
Investments 231.86 410.47 474.01 619.39 733.41
Loans & Advances 128.11 125.65 183.45 118.52 227.77
Other N/C Assets 5.96 11.18 24.28 25.83 8.96
Current Assets 2285.55 2712.11 3277.79 4224.46 4875.15
Total Assets 4457.54 5184.57 6010.13 7438.44 8446.97
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 557.39 784.97 1379.96 1074.11 750.49
Adjustment 174.79 180.77 172.5 221.16 206.09
Changes in Assets & Liabilities -128.87 -257.9 -214.53 -271.39 20.96
Tax Paid -107.66 -146.41 -241.87 -192.16 -215.25
Operating Cash Flow 495.65 561.43 1096.06 831.72 762.29
Investing Cash Flow -122.98 -499.13 -559.56 -811.85 -709.61
Financing Cash Flow -222.83 -138.67 -307.38 426.04 506.38
Net Cash Flow 149.84 -76.37 229.12 445.91 559.06

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 46.29 46.29 46.29 46.29 46.30
chandurkar investments pr... - - 5.50 5.50 5.50
kalpana jain 0.09 0.09 0.09 0.09 0.09
kaygee investments privat... - - 21.47 21.47 21.47
kaygee laboratories priva... - - 6.61 6.61 6.61
mexin medicaments private... - - 0.01 0.01 0.01
paschim chemicals pvt ltd... - - 4.00 4.00 4.01
pranay godha 0.67 0.67 0.67 0.67 0.67
prashant godha 0.62 0.62 0.62 0.62 0.62
premchand godha 2.29 2.29 2.29 2.29 2.29
sameer m chandurkar 0.79 0.79 0.79 0.79 0.79
usha m chandurkar 3.27 3.27 3.27 3.27 3.27
usha premchand godha 0.95 0.95 0.95 0.95 0.95
xbees traders llp - - 0.01 0.01 0.01
chandurkar investments pv... 5.50 5.50 - - -
kaygee investments pvt. l... 21.47 21.47 - - -
kaygee laboratories pvt. ... 6.61 6.61 - - -
mexin medicaments pvt. lt... 0.01 0.01 - - -
paschim chemicals pvt. lt... 4.00 4.00 - - -
xbees traders llp (former... 0.01 0.01 - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 53.71 53.71 53.71 53.71 53.70
abu dhabi investment auth... - - - 1.03 1.12
dsp midcap fund 5.51 6.65 6.73 6.90 7.13
hdfc life insurance compa... 1.96 1.90 1.90 1.97 1.95
hdfc mutual fund - hdfc m... - 6.64 7.22 7.27 7.03
icici prudential multi-as... 2.48 3.69 3.14 2.74 2.40
investor education and pr... - 0.31 - - 0.30
kotak emerging equity sch... 3.13 3.20 3.64 3.71 3.70
kotak funds - india midca... - 1.21 1.29 1.29 1.36
llp 0.03 0.04 0.04 0.07 0.04
nippon life india trustee... 2.24 2.07 1.47 1.62 1.70
parag parikh flexi cap fu... 1.26 1.46 1.46 1.46 1.46
sbi life insurance co. lt... - 1.42 1.67 1.73 1.83
uti flexi cap fund 1.52 1.46 1.08 1.13 1.04
investor education and pr... 0.31 - 0.30 0.30 -
mirae asset emerging blue... 1.44 1.31 1.86 - -
axis mutual fund trustee ... 1.65 - - - -
canara robeco mutual fund... 1.04 - - - -
hdfc trustee company ltd ... 5.49 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Ipca Laboratories informs about compliance certificate22 Apr 2024, 12:32PM Ipca Laboratories enters into Technology Transfer Agreement with Omexa Formulary27 Mar 2024, 3:14PM Ipca Laboratories informs about trading window closure 21 Mar 2024, 3:17PM Ipca Laboratories informs about press release27 Feb 2024, 4:34PM IPCA Laboratories informs about postal ballot notice 27 Feb 2024, 1:03PM Ipca Laboratories informs about notice of postal ballot23 Feb 2024, 2:50PM Ipca Laboratories informs about audio recording of conference call16 Feb 2024, 10:42AM Ipca Laboratories - Quaterly Results14 Feb 2024, 1:42PM Ipca Laboratories - Quaterly Results14 Feb 2024, 1:42PM Ipca Laboratories - Quaterly Results14 Feb 2024, 1:42PM lpca Laboratories informs about loss of share certificate 25 Jan 2024, 2:20PM IPCA Laboratories submits board meeting intimation 22 Jan 2024, 2:52PM Ipca Laboratories informs about compliance certificate10 Jan 2024, 2:33PM Ipca Laboratories informs about loss of share certificate22 Nov 2023, 3:23PM Ipca Laboratories informs about press release13 Nov 2023, 5:01PM Ipca Laboratories reports 6% fall in Q2 consolidated net profit13 Nov 2023, 3:12PM Ipca Laboratories informs about loss of share certificate13 Nov 2023, 2:51PM Ipca Laboratories - Quaterly Results10 Nov 2023, 1:39PM Ipca Laboratories - Quaterly Results10 Nov 2023, 1:39PM Ipca Laboratories - Quaterly Results10 Nov 2023, 1:39PM Ipca Laboratories gets VAI classification for Indore facility31 Oct 2023, 11:52AM Ipca Laboratories informs about disclosure 31 Oct 2023, 10:07AM Ipca Laboratories informs about board meeting 25 Oct 2023, 5:02PM Ipca Laboratories gets VAI classification for Madhya Pradesh facility23 Oct 2023, 11:40AM Ipca Laboratories gets VAI classification for Piparia manufacturing facility24 Aug 2023, 10:21AM Ipca Laboratories - Quaterly Results10 Aug 2023, 1:08PM Ipca Laboratories - Quaterly Results10 Aug 2023, 1:08PM Ipca Laboratories - Quaterly Results10 Aug 2023, 1:08PM Ipca Laboratories acquires 33.38% stake in Unichem Laboratories3 Aug 2023, 10:30AM IPCA Laboratories informs about disclosure 27 Jul 2023, 9:32AM Ipca Laboratories informs about annual report10 Jul 2023, 9:41AM USFDA conducts inspection at Ipca Laboratories’ formulations manufacturing facility in Pithampur24 Jun 2023, 10:51AM Ipca Laboratories informs about inspection of Company’s manufacturing facility 14 Jun 2023, 9:43AM USFDA conducts inspection at Ipca Laboratories’ APIs manufacturing facility at Ratlam14 Jun 2023, 9:31AM Ipca Laboratories informs about newspaper publication 2 Jun 2023, 10:29AM Ipca Laboratories informs about cancellation of conference call30 May 2023, 5:15PM Ipca Laboratories - Quaterly Results29 May 2023, 1:40PM Ipca Laboratories - Quaterly Results29 May 2023, 1:40PM Ipca Laboratories - Quaterly Results29 May 2023, 1:40PM Ipca Laboratories informs about updates 27 Apr 2023, 9:59AM USFDA conducts inspection at Ipca Laboratories’ formulations manufacturing unit at Piparia27 Apr 2023, 9:24AM Ipca Laboratories inks pact to acquire 33.4% stake in Unichem Laboratories24 Apr 2023, 4:58PM Ipca Laboratories informs about closure of trading window 31 Mar 2023, 10:02AM Ipca Laboratories - Quaterly Results14 Feb 2023, 1:07PM Ipca Laboratories - Quaterly Results14 Feb 2023, 1:07PM Ipca Laboratories - Quaterly Results14 Feb 2023, 1:07PM Ipca Laboratories informs about conference call9 Feb 2023, 5:06PM Ipca Laboratories acquires further 6.53% stake in Trophic Wellness20 Dec 2022, 9:21AM Ipca Laboratories - Quaterly Results11 Nov 2022, 1:24PM Ipca Laboratories - Quaterly Results11 Nov 2022, 1:24PM

Ipca Laboratories Stock Price Analysis and Quick Research Report. Is Ipca Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ipca Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ipca Laboratories cash from the operating activity was Rs 762.29 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ipca Laboratories has a Debt to Equity ratio of 0.2421 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ipca Laboratories , the EPS growth was -41.2229564560978 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ipca Laboratories has OPM of 15.3794469688574 % which is a good sign for profitability.
     
  • ROE: Ipca Laboratories have a poor ROE of 8.90861142282345 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ipca Laboratories is Rs 1347.25. One can use valuation calculators of ticker to know if Ipca Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Ipca Laboratories

Ipca Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Ipca Laboratories Ltd. is a leading pharmaceutical company in India that specializes in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs).  We will take a closer look at Ipca Laboratories Ltd. stock analysis page and explore various aspects of the company that can help long-term investors make informed investment decisions.

Ipca Laboratories Ltd Share Price

Ipca Laboratories Ltd.'s share price has been on a steady upward trend in recent years. The company's strong financial performance and growth prospects have attracted a lot of investor interest, leading to an increase in demand for its shares. Investors can track the company's share price on Ticker's stock analysis page, which provides real-time updates on the stock's performance.

Ipca Laboratories Ltd Balance Sheet

Ipca Laboratories Ltd.'s balance sheet is a reflection of its financial health and stability. The company has a strong balance sheet, with a healthy mix of debt and equity. Ticker pre-built screening tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis can help investors evaluate the company's financial performance and calculate its fair value. Investors can access the company's balance sheet on Ticker's stock analysis page, along with other financial data such as quarterly results and profit and loss statements.

Ipca Laboratories Ltd Annual Report

Ipca Laboratories Ltd.'s annual report provides a comprehensive overview of the company's performance over the past year. The report includes detailed information on the company's financials, operations, and growth prospects. Investors can download the company's annual report from Ticker's stock analysis page. The report can help investors gain a better understanding of the company's business model, competitive landscape, and growth potential.

Ipca Laboratories Ltd Dividend

Ipca Laboratories Ltd. has a track record of paying dividends to its shareholders. The company's dividend policy is based on its financial performance and growth prospects. Investors can access the company's dividend history on Ticker's stock analysis page. 

Ipca Laboratories Ltd Quarterly Result

Ipca Laboratories Ltd.'s quarterly results provide a snapshot of the company's financial performance over the past quarter. The results include information on the company's revenue, profits, and margins. Investors can download the company's quarterly results from Ticker's stock analysis page. Ticker pre-built screening tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach and DuPont analysis can help investors evaluate the company's financial performance and calculate its fair value.

Ipca Laboratories Ltd Stock Price

Ipca Laboratories Ltd.'s stock price is a reflection of its financial performance and growth prospects. The company's stock price is influenced by various factors such as market trends, investor sentiment, and the company's financials. Investors can track the company's stock price on Ticker's stock analysis page, which provides real-time updates on the stock's performance.

Ipca Laboratories Ltd Price Chart

Ipca Laboratories Ltd.'s price chart provides a visual representation of the company's stock price movement over a period. The chart includes information on the company's stock price, volume, and trends. Investors can access the company's price chart on Ticker's stock analysis page. The chart can help investors gain insights into the company's stock price movement and identify trends.

Ipca Laboratories Ltd News

Ipca Laboratories Ltd.'s news section provides updates on the company's latest developments and announcements. The section includes information on the company's product launches, partnerships, and collaborations. Investors can access the company's news section on Ticker's stock analysis page. The news section can help investors stay updated on the company's latest developments and make informed investment decisions.

Ipca Laboratories Ltd Concall Transcripts

Ipca Laboratories Ltd.'s concall transcripts provide a detailed account of the company's earnings conference call. The transcripts include information on the company's financial performance, growth prospects, and future plans. Investors can download the company's concall transcripts from Ticker's stock analysis page. The transcripts can help investors gain insights into the company's performance and future prospects.

Ipca Laboratories Ltd Investor Presentations

Ipca Laboratories Ltd.'s investor presentations provide a detailed overview of the company's business model, operations, and growth prospects. The presentations include information on the company's financials, product portfolio, and competitive landscape. Investors can download the company's investor presentations from Ticker's stock analysis page. The presentations can help investors gain a better understanding of the company's business model and growth potential.

Ipca Laboratories Ltd Promoters

Ipca Laboratories Ltd.'s promoters are the key drivers of the company's growth and success. The promoters have a significant stake in the company and are actively involved in its operations and decision-making. Investors can access information on the company's promoters on Ticker's stock analysis page. The information can help investors evaluate the promoters' track record and their contribution to the company's growth.

Ipca Laboratories Ltd Shareholders

Ipca Laboratories Ltd.'s shareholders are the owners of the company and have a stake in its financial performance and growth prospects. The company has a diverse shareholder base, including institutional investors and retail investors. Investors can access information on the company's shareholders on Ticker's stock analysis page. The information can help investors evaluate the company's shareholder base and their contribution to the company's growth.

Read More
X